Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Petroni

Showing results (101-110 of 124) with videos related to

Pageof 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2007
Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant settingCraig L Slingluff, Gina R Petroni, Kimberly A Chianese-Bullock, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 9, 2008
A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancerKimberly A Chianese-Bullock, William P Irvin, Gina R Petroni, et al.
Brachytherapy|June 24, 2020
Toxicity and cosmetic outcomes after treatment with a novel form of breast IORTMax O Meneveau, Gina R Petroni, Nikole E Varhegyi, et al.
Journal for Immunotherapy of Cancer|September 13, 2022
Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)Rick Daniel Vavolizza, Gina R Petroni, Ileana S Mauldin, et al.
Journal for Immunotherapy of Cancer|November 22, 2017
A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancerPatrick M Dillon, Gina R Petroni, Mark E Smolkin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2008
Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigensCraig L Slingluff, Gina R Petroni, Walter Olson, et al.
Annals of Surgical Oncology|October 17, 2008
Evaluation of the sentinel immunized node for immune monitoring of cancer vaccinesCraig L Slingluff, Galina V Yamshchikov, Kevin T Hogan, et al.
Journal for Immunotherapy of Cancer|August 20, 2021
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanomaSapna P Patel, Gina R Petroni, Jason Roszik, et al.
Cancer Research Communications|April 10, 2026
Randomized phase I/II clinical trial of a melanoma helper peptide vaccine with or without systemic agonistic anti-CD27 antibody (varlilumab)Emily K Ninmer, Gina R Petroni, Elizabeth Gaughan, et al.
Cancer|September 10, 2020
Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancerLinda R Duska, Jennifer M Scalici, Sarah M Temkin, et al.
Pageof 13

Showing results (101-110 of 124) with videos related to

Sort By:
Pageof 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2007
Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant settingCraig L Slingluff, Gina R Petroni, Kimberly A Chianese-Bullock, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 9, 2008
A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancerKimberly A Chianese-Bullock, William P Irvin, Gina R Petroni, et al.
Brachytherapy|June 24, 2020
Toxicity and cosmetic outcomes after treatment with a novel form of breast IORTMax O Meneveau, Gina R Petroni, Nikole E Varhegyi, et al.
Journal for Immunotherapy of Cancer|September 13, 2022
Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)Rick Daniel Vavolizza, Gina R Petroni, Ileana S Mauldin, et al.
Journal for Immunotherapy of Cancer|November 22, 2017
A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancerPatrick M Dillon, Gina R Petroni, Mark E Smolkin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2008
Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigensCraig L Slingluff, Gina R Petroni, Walter Olson, et al.
Annals of Surgical Oncology|October 17, 2008
Evaluation of the sentinel immunized node for immune monitoring of cancer vaccinesCraig L Slingluff, Galina V Yamshchikov, Kevin T Hogan, et al.
Journal for Immunotherapy of Cancer|August 20, 2021
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanomaSapna P Patel, Gina R Petroni, Jason Roszik, et al.
Cancer Research Communications|April 10, 2026
Randomized phase I/II clinical trial of a melanoma helper peptide vaccine with or without systemic agonistic anti-CD27 antibody (varlilumab)Emily K Ninmer, Gina R Petroni, Elizabeth Gaughan, et al.
Cancer|September 10, 2020
Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancerLinda R Duska, Jennifer M Scalici, Sarah M Temkin, et al.
Pageof 13